Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01451151 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542)
A Phase 2 study of Androgenetic Alopecia and Male Pattern Baldness, sponsored by Aderans Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 2
- Study locations
NCT01451151 is a Phase 2 study of Androgenetic Alopecia and Male Pattern Baldness that has completed, run by Aderans Research Institute. The registered enrollment target is 33 participants, below the 163-participant average among 16 other Androgenetic Alopecia trials with a reported enrollment target (80% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01451151, a Phase 2 study of Androgenetic Alopecia and Male Pattern Baldness, has completed, sponsored by Aderans Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of the the study is to evaluate the ability of injections of Ji Gami(TM) C to induce hair growth in male and female subjects with hair loss.
Conditions Studied
Interventions
- BIOLOGICAL Autologous cultured dermal and epidermal cells
Study Locations (2)
California
- Axis Clinical Trials, Inc. - Los Angeles
New York
- Axis Clinical Trials, Inc. - New Hyde Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01451151
The ClinicalTrials.gov registry entry for NCT01451151 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 163-participant average among 16 other Androgenetic Alopecia trials with a reported enrollment target (80% lower). The listed sponsor is Aderans Research Institute, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Androgenetic Alopecia appearing as the primary indexed condition, and to 1 intervention - of which Autologous cultured dermal and epidermal cells is the first listed.
NCT01451151 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, New York.
Frequently Asked Questions
What is clinical trial NCT01451151 about?
NCT01451151 is a clinical study titled "A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542)". The purpose of the the study is to evaluate the ability of injections of Ji Gami(TM) C to induce hair growth in male and female subjects with hair loss.
What is the current status of trial NCT01451151?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2010-12.
What conditions does trial NCT01451151 study?
This clinical trial studies the following conditions: Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness.
What interventions are being tested in trial NCT01451151?
The interventions under investigation include: Autologous cultured dermal and epidermal cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT01451151?
This trial is sponsored by Aderans Research Institute, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01451151 being conducted?
This trial has 2 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Androgenetic Alopecia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy of VDPHL01 in Males and Females With AGA
ACTIVE NOT RECRUITING · Phase 2
-
Use of Botulinum Toxin in the Treatment of Androgenic Alopecia
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy and Safety of VDPHL01 in Males With AGA
ACTIVE NOT RECRUITING · Phase 2
-
A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing
COMPLETED · Phase 2
-
Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA
COMPLETED · Phase 2
-
A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.